Global Cartilage Repair Market 2017-2021
About Cartilage Repair
Cartilage is a smooth elastic muscle, which covers the ends of the bone and serves as a bearing surface of the joint. Articular cartilage is produced by chondrocytes. Chondrocytes are the cells that divide and multiply very slowly as they do not have blood vessels. This is one of the reasons articular cartilage injuries do not repair well and can lead to continued degradation and deterioration of joint condition, leaving few treatment options available for the patients. The treatment of articular cartilage has evolved tremendously in the past decade. Reparative and restorative methods have been developed to address the significant source of morbidity in the young and active patients. Articular cartilage injury can be focal, which is localized or systemic. Procedures are being developed not only to alleviate the symptoms associated with articular cartilage defects but also to limit the progression of cartilage damages into degenerative diseases.
Technavio’s analysts forecast the global cartilage repair market to grow at a CAGR of 11.59 % during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global cartilage repair market for 2017-2021. To calculate the market size, the report considers the new sales/value of cartilage repair market.The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Cartilage Repair Market 2017-2021
Technavio recognizes the following companies as the key players in the global cartilage repair market: Acelity, DePuy Synthes, Stryker, and Smith & Nephew
Other Prominent Vendors in the market are: AlloSource, Bio-Tissue, CellGenix, Collagen Solutions, Geistlich Pharma, Orteq, RTI Surgical, TORNIER, Vericel, and XTANT MEDICAL.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Gene therapy and stem cell therapy. Gene therapy is one of the promising fields in the cartilage repair. Many clinical studies have been performed for cartilage repair. The researchers are trying to develop gene therapy for cartilage repair and currently been investigated for clinical application. For osteoarthritis, five gene therapeutic targets that enhance chondrogenesis have been extensively studied such as growth factors that includes TGF-β, BMP, FGF, IGF-1, and epidermal growth factor (EGF), transcription factors such as SOX9, signal transduction molecules – SMADs, pro-inflammatory cytokine inhibition such as TNF-α and IL-1β and apoptosis or senescence inhibition such as Bcl-2, Bcl-XL, and inducible nitric oxide synthase (iNOS).”
According to the report, one of the major drivers for this market is Rising incidence of accidental injuries. Globally, the road traffic injuries are increasing, with post complicated symptoms such as weakening of tendons, cartilage tear, and orthopedic issues. According to the CDC (2016), each year on an average of 20-30 million people are injured and disabled by roadways and the cost of road injuries is estimated to be $518 billion per year. It also stated that the US, New Zealand, Canada, France, Japan, and Germany have seen more number of injuries and deaths due to road injuries.
Further, the report states that one of the major factors hindering the growth of this market is Product side effects. Surgeons use cartilage repair products such as tissue scaffold to improve the recovery. These products once grafted in the body may cause serious complications, resulting in their increased scrutiny for safety and efficacy. In many autologous chondrocyte implantation, there were common complications such as graft rejection, symptomatic hypertrophy, disturbed fusion and delamination.
Acelity, DePuy Synthes, Stryker, Smith & Nephew, AlloSource, Bio-Tissue, CellGenix, Collagen Solutions, Geistlich Pharma, Orteq, RTI Surgical, TORNIER, Vericel, and XTANT MEDICAL.